XML 76 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative Arrangements - Financial Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 48,704 $ 41,518 $ 39,121
Cost of sales 13,626 13,618 12,016
Selling, general and administrative 9,634 8,955 9,455
Research and development 12,245 13,397 9,724
Payables included in Accrued and other liabilities 23,872 27,327  
Amortization expense for intangible assets 1,600 1,800 1,700
Other current assets | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 271 215  
Other current assets | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 200 157  
Other current assets | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 114 65  
Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 415 423  
Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 625 335  
Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 472 0  
Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 283 3  
Other Noncurrent Liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Other Noncurrent Liabilities 0 600  
Total sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 1,018 733 444
Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 989 725 444
Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 29 8 0
Total sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 704 580 404
Total sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 342 281 204
Sales 601 501 419
Total sales | Bayer AG | Collaborative Arrangement | Adempas      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 252 220 215
Total sales | Bayer AG | Collaborative Arrangement | Verquvo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 7 0 0
Total sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Molnupiravir      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 952 0  
Cost of sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 167 247 148
Cost of sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 195 271 206
Cost of sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 424 196 188
Amortization expense for intangible assets 153    
Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 494 13  
Selling, general and administrative | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 178 160 138
Selling, general and administrative | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 127 73 80
Selling, general and administrative | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 126 47 34
Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 33 6  
Research and development | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 120 133 168
Research and development | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 173 185 189
Research and development | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 53 63 $ 126
Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development $ 60 $ 323